

DOCKET NO.: CP380H  
Application No.: 10/789,628  
Office Action Dated: July 11, 2006

PATENT

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1. (currently amended) A method of treating ~~cancer~~ lymphoma in a human, which comprises administering to the human a combination of (i) a therapeutically effective amount of ~~one or more arsenic compounds~~ trioxide, and (ii) all trans-retinoic acid.
2. (canceled)
3. (currently amended) The method of ~~claim 2~~ claim 1, wherein the arsenic trioxide is formulated as an ionic aqueous solution.
4. (currently amended) The method of claim 1, wherein the total daily amount administered of the arsenic ~~compound~~ trioxide is from about 10 g  $\mu$ g to about 200 mg.
5. (currently amended) The method of claim 1, wherein the total daily amount administered of the arsenic ~~compound~~ trioxide is from about 0.5 mg to about 150 mg.
6. (currently amended) The method of claim 1, wherein the total daily amount administered of the arsenic ~~compound~~ trioxide is from about 0.5 mg to about 70 mg.
7. (currently amended) The method of claim 1, wherein the arsenic ~~compound~~ trioxide is administered parenterally.
8. (currently amended) The method of claim 1, wherein the arsenic ~~compound~~ trioxide is administered intravenously.
9. (currently amended) The method of claim 1, wherein the all trans-retinoic acid and the arsenic ~~compound~~ trioxide are administered in combination with an effective amount of at least one further therapeutic agent.

DOCKET NO.: CP380H  
Application No.: 10/789,628  
Office Action Dated: July 11, 2006

PATENT

10. (original) The method of claim 9, wherein the further therapeutic agent is a chemotherapeutic or radiotherapeutic.
11. (original) The method of claim 9, wherein the further therapeutic agent is selected from the group consisting of etoposide, cisplatin, carboplatin, estramustine phosphate, vinblastine, methotrexate, hydroxyurea, cyclophosphamide, doxorubicin, 5-fluorouracil, taxol, diethylstilbestrol, VM-26(vumon), BCNU, procarbazine, cytokines, therapeutic vaccines, and immunomodulators.
12. (currently amended) The method of ~~claim 2~~ claim 1, wherein the dose of the arsenic trioxide is varied according to the body weight of the human.
- 13-19. (canceled)
20. (currently amended) The method of ~~claim 2~~ claim 1, wherein the ~~cancer~~ lymphoma has metastasized.